Summary (tl;dr)

Medvi, a telehealth company specializing in GLP-1 weight-loss drugs, is rapidly trending after a New York Times profile highlighted its projected $1.8 billion in annual sales for 2026, achieved primarily through extensive use of AI and an ultra-lean two-person operation.

Essential Background

The telehealth market for weight-loss medications, particularly GLP-1 drugs like semaglutide and tirzepatide, has seen significant growth with established players already in the field. In early 2024, OpenAI CEO Sam Altman famously predicted the emergence of one-person, billion-dollar companies, largely powered by artificial intelligence. This context sets the stage for Medvi's groundbreaking success.

The Full Story

Medvi was founded in September 2024 by Matthew Gallagher with an initial investment of just $20,000. Leveraging over a dozen AI tools, including ChatGPT, Claude, and Grok for coding, Midjourney and Runway for ad creatives, and ElevenLabs for customer communication, Gallagher automated nearly every aspect of the business. Medvi reported $401 million in revenue in its first full calendar year (2025) serving 250,000 customers, with a net profit of 16.2%, or $65 million, and is now on track for $1.8 billion in sales for 2026. The company operates with minimal staff—Gallagher and his brother being the only full-time employees—by outsourcing its clinical infrastructure, including licensed physicians, prescription processing, pharmacy fulfillment, and regulatory compliance, to platforms like CareValidate and OpenLoop Health. This unprecedented growth and operational efficiency were recently detailed in a New York Times profile, validating Altman's prediction and sparking widespread interest in Medvi's business model.

Why It Matters

Medvi's success is a significant indicator of AI's disruptive potential, demonstrating how it can enable individuals to build and scale highly profitable businesses with minimal human capital, fundamentally challenging traditional corporate structures. The company's rapid ascent highlights the growing importance of AI fluency for entrepreneurs and could inspire a new wave of lean, AI-powered startups across various sectors. However, this model also raises important questions about regulatory oversight in the telehealth industry, particularly concerning the marketing of compounded GLP-1 drugs and the use of AI-generated content in advertising, with some venture capitalists expressing concerns about potential regulatory navigation and the legality of certain marketing practices. Critics point out Medvi's lack of proprietary technology or exclusive partnerships, suggesting its model could be vulnerable to replication.

Geographic Location

• Los Angeles, Los Angeles County, California, United States (founder Matthew Gallagher built Medvi from his home)
• New York, New York County, New York, United States (New York Times published the profile on Medvi)